J H Machiels

Suggest Changes
Learn More
4525^ Background: Docetaxel is standard first-line chemotherapy for mCRPC. The Phase III TROPIC trial showed that, for patients who progressed during or after docetaxel-based therapy, cabazitaxel(More)
4622 Background: Dysregulation of mammalian Target of Rapamycin (mTOR) pathway plays a role in TCC development. We assessed the efficacy and toxicity of Everolimus (E), an oral mTOR inhibitor, in(More)
144^ Background: The phase III TROPIC study showed that cabazitaxel plus prednisone (CbzP) improves survival compared with mitoxantrone plus prednisone (MP) in men with mCRPC who progressed after(More)
314 Background: The mammalian target of rapamycin (mTOR) inhibitor everolimus is the first agent to show efficacy in a randomized, controlled phase III trial in patients with mRCC after progression(More)
4601 Background: The phase III RECORD-1 trial established everolimus as the only agent proven to benefit patients with metastatic renal cell carcinoma (mRCC) after failure of initial VEGFr-TKI(More)
4526^ Background: The Phase III TROPIC trial showed that cabazitaxel plus prednisone (CbzP) significantly improved overall survival (OS) compared with mitoxantrone plus prednisone (MP) in men with(More)
4660 Background: The 2 most popular prognostic systems for patients with metastatic renal cell carcinoma (mRCC) are MSKCC and French Group of Immunotherapy (FGI) models. Both systems have initially(More)
e15131^ Background: The Phase III TROPIC trial demonstrated that cabazitaxel plus prednisone (CbzP) improved overall survival compared with mitoxantrone plus prednisone (MP) in patients with mCRPC(More)
LBA5506 Background: Zalutumumab is a novel, fully human IgG1 mAb targeting the EGFr that has shown encouraging activity in SCCHN. METHODS Patients with noncurable SCCHN with an ECOG PS of 0-2 and(More)